Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NVZMF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NVZMF and 80,000+ other tickers.
See exactly how NVZMF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NVZMF and 80,000+ other tickers.
Novozymes A/S, a Danish enterprise established in 1925 and headquartered in Bagsvaerd, is a leading provider of biological solutions, specializing in the production and global distribution of industrial enzymes, microorganisms, and probiotics. Its extensive reach spans across Europe, the Middle East, Africa, North America, Asia Pacific, and Latin America. The company's diverse portfolio caters to a wide array of sectors, including the food and beverage industry with innovations for baking, beverages, dairy, starch processing, and protein applications. In household care, its products enhance…
Novozymes A/S (OTCMKTS:NVZMF - Get Free Report)'s stock price passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $62.49 and traded as low as $60.49. Novozymes A/S shares last traded at $60.49, with a volume of 214 shares. Novozymes A/S Trading Up 1.1%
Novonesis A/S (OTCPK:NVZMF) Q2 2025 Earnings Conference Call August 21, 2025 3:00 AM ET Company Participants Anders Lund - Chief Operating Officer Andrew Taylor - Corporate Participant Claus Crone Fuglsang - Chief Scientific Officer Ester Baiget - President & CEO Henrik Joerck Nielsen - Corporate Participant EVP of Human Health Biosolutions and Strategy & Integration - Corporate Participant Morten Enggaard Rasmussen - Executive Vice President of People & Stakeholder Relations Rainer Lehmann - Executive VP & CFO Tina Sejersgaard Fano - Executive Vice President of Planetary Health Biosolutions Tobias Cornelius Bjorklund - Head of Investor Relations Conference Call Participants Alexander Morrow Sloane - Barclays Bank PLC, Research Division Chetan Udeshi - JPMorgan Chase & Co, Research Division Georgina Fraser - Goldman Sachs Group, Inc., Research Division Lars Topholm - Carnegie Investment Bank AB, Research Division Nicola Tang - BNP Paribas Exane, Research Division Ranulf Orr - Citigroup Inc., Research Division Soren Samsoe - SEB, Research Division Thomas Lind Petersen - Nordea Markets, Research Division Thomas P. Wrigglesworth - Morgan Stanley, Research Division Operator Good morning, ladies and gentlemen, and welcome to the Novonesis Conference Call regarding the first half 2025 financial results as well as the 2030 growth strategy.
Novonesis A/S (OTCPK:NVZMF) Q1 2025 Earnings Conference Call May 8, 2025 3:00 AM ET Company Participants Tobias Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Rainer Lehmann - Chief Financial Officer Amy Byrick - Executive Vice President, Human Health Biosolutions Tina Fano - Executive Vice President, Planetary Health Biosolutions Claus Crone Fuglsang - Chief Scientific Officer Conference Call Participants Alex Sloane - Barclays Matthew Yates - Bank of America Thomas Lind Petersen - Nordea Charles Eden - UBS Ranulf Orr - Citibank Søren Samsøe - SEB Nicola Tang - BNP Paribas Chetan Udeshi - JP. Morgan André Thormann - Danske Bank Operator Tobias Björklund Thank you very much, operator, and welcome, everyone, to the Novonesis Conference Call for the First Quarter of 2025.
Novonesis A/S (OTCPK:NVZMF) Q4 2024 Earnings Conference Call February 26, 2025 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Rainer Lehmann - Chief Financial Officer Jacob Paulsen - Executive Vice President, Food & Beverage Biosolutions Amy Byrick - Executive Vice President, Human Health Biosolutions Tina Fano - Executive Vice President, Planetary Health Biosolutions Claus Crone Fuglsang - Chief Scientific Officer Conference Call Participants Alex Jones - Bank of America Søren Samsøe - SEB Charles Eden - UBS Thomas Lind - Nordea Sebastian Bray - Berenberg Lars Topholm - Carnegie Alex Sloane - Barclays Chetan Udeshi - JPMorgan André Thormann - Danske Bank Georgina Fraser - Goldman Sachs Operator Ladies and gentlemen, welcome to the Novonesis Full Year Financial Statement for 2024 and Annual Report 2024 Conference Call. I'm Youssef, the Chorus Call operator.
Novonesis A/S (OTCPK:NVZMF) Q3 2024 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Rainer Lehmann - Chief Financial Officer Jacob Paulsen - Executive Vice President, Food & Beverage Biosolutions Amy Byrick - Executive Vice President, Human Health Biosolutions Tina Fano - Executive Vice President, Planetary Health Biosolutions Claus Crone Fuglsang - Chief Scientific Officer Conference Call Participants Alex Jones - Bank of America Thomas Lind Petersen - Nordea Charles Eden - UBS Søren Samsøe - SEB Chetan Udeshi - JPMorgan Lars Topholm - Carnegie Investment Bank Nicola Tang - BNP Paribas Exane Georgina Fraser - Goldman Sachs Charles Bentley - Jefferies Operator Welcome to the Novonesis Interim Report for the First Nine Months of 2024 Conference Call. Throughout, all participants will be in listen-only mode and afterwards there will be a question-and-answer session.